ONCOC4, INC.

ROCKVILLE, MD · Founded 2020 · CIK 0001839078 · Biotech · Private

ONC-392, a novel anti-CTLA-4 monoclonal antibody that preserves immune checkpoint function while selectively depleting regulatory T cells in tumors

oncoc4.com →
Grants
$2.0M
2 awards
Sector median: 1
Raised
$50M
1 Form D · Jan 2021
69 months since last filing
Contracts
—
No federal contracts on record
Patents
29
2 granted · 27 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$50,000,000
Federal grantDepartment of Health and Human Services · Phase II · First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3269Outer Biosciences Inc—$23M
3270Prelenia——
3271Ophysio Inc.——
3272ONCOC4, INC.—$50M
3273CLUE GENETICS INC.——
3274Ibex Investment Holdings LLC—$5.0M
3275Lucidicor Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Martin DevenportExecutive Officer
  • Michael FlaschenDirector
  • Yang LiuDirector · Executive Officer

Patents

USPTO · 2 granted of 29
  • Composition and Method for Synthesizing Pegylated Uricase-Drug Conjugates to Mitigate Anti-Drug Antibody and Their Therapeutic Useapplication
  • ANTI-CTLA-4 Antibody Dosing Regimensapplication
  • Use Of ANTI-CTLA-4 Antibodies For Treating Adenoid Cystic Carcinomaapplication
  • Method Of Abrogating Anti-drug Antibody Formation, And Drug Conjugates For Use Thereinapplication
  • Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereofgranted
  • Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses Thereofgranted
  • Uses Of Hypoxia-inducible Factor Inhibitorsapplication
  • Ph-sensitive ANTI-CTLA-4 Antibodies And Uses Thereofapplication
  • Combinations Of ANTI-CTLA-4 Antibodies And ANTI-PD-1 Antibodies And Therapeutic Uses Thereofapplication
  • Anti-vegf And PD-1 Bispecifc Antibodies And Uses Thereofapplication
  • ANTI-CD24 Antibody Drug Conjugates And Uses Thereofapplication
  • ANTI-CD24/ANTI-CD3 Bispecific Binding Proteins And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.